alternatives to glp-1 drugs from the Gray Market GLP-1 Medications for Weight Loss

38 A significant reduction in ICP was seen acutely at 2.5 h of 4.2 mmHg (equivalent to 5.7 cmCSF), which corresponds to peak exenatide serum levels

Detailed forest plots for all secondary outcomes, subgroup analysis and ITCA 650 sensitivity analysis are included in Supplementary Appendix D, except pooled analysis of cardiovascular mortality where this is included in Fig

According to Basilico, the effect GLP-1 drugs have on patients' appetites means there needs to be added emphasis on nutrition

Research has identified specific gene variants associated with GLP-1 drug response, but pharmacogenomic testing for GLP-1 medications is not yet standard clinical practice

In January 2025, Novo Nordisk disclosed key findings from the STEP UP study , a Phase IIIb trial within the global STEP program

Studies are also underway for a spectrum of other conditions, including Phase 3 trials investigating non-alcoholic steatohepatitis (NASH), chronic kidney disease (CKD), and obstructive sleep apnea (OSA), as well as mid-to-late stage trials exploring potential benefits in neurodegenerative disorders like Parkinsons disease